Advertisement

Picture EBD Group ChinaBio Partnerting Forum 2021 651x80

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3067 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 29 30 31  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Cellectis–Sirion Biotech: cell/gene therapy manufacturing technology, 202101– non-excl license €na to LentiBoost technology for CAR-T cell therapies 2021-01-07
Sterna Biologicals–SEVERAL: investment, 202101 financing round Series A 2nd closing €10m bringing total Series A to €22m 2021-01-07
Adeptrix–Bruker: investment, 202101 financing round Series A incl new + minority investor Bruker Corp 2021-01-06
Adeptrix–SEVERAL: investment, 202101 financing round Series A closed with new + minority investor Bruker Corp 2021-01-06
Eleva–Zukunftsfonds Heilbronn: investment, 202101– up to €60m for development of CPV-101 2021-01-06
Somatex Medical Technologies–Hologic: investment, 202101 acquisition $64m of Somatex by Hologic 2021-01-04
Biosun Biochemicals–BRAIN: investment, 202101 acquisition 100% €na by BRAIN AG 2021-01-01
Qiagen–Wellcome Trust: COSMIC Database, 202101– distribution excl rights to license + distribute COSMIC for commercial use 2021-01-01
SomaLogic–Novartis: investment, 202012 financing round Series A 2nd closing totalling addit $81m incl Novartis 2020-12-22
SomaLogic–SEVERAL: investment, 202012 financing round Series A 2nd closing additional $81m bringing total Series A to $204m or $214m 2020-12-22
Evotec–Alloy Therapeutics: transgenic mouse technolgy, 202012– supply access to ATX-Gx platform to expand Evotec antibody discovery platform 2020-12-21
Peptilogics–Angermayer Group: investment, 202012 financing round Series B totalling $35.4m incl new + lead investor Presight Capital 2020-12-21
Peptilogics–SEVERAL: investment, 202012 financing round Series B $35.4m led by Presight Capital 2020-12-21
Cadent Therapeutics–Novartis: investment, 202012– acquisition $210m upfront + $560m milestones ANNOUNCED 2020-12-17
Neuron23–SEVERAL: investment, 202012 financing round Series B $80m led by new investor Redmile Group 2020-12-16
MYR GmbH–Gilead Sciences: investment, 202012 acquisition €1.15b in cash + €300m milestones of MYR GmbH by Gilead Sciences Inc 2020-12-10
NBE Therapeutics–Boehringer: investment, 202012– acquisition up to €1.18b by Boehringer 2020-12-10
Resolve Biosciences–Alafi Capital: investment, 202012 financing round Series A totalling $24m incl co-investor Alafi Capital 2020-12-10
Resolve Biosciences–Bioscribe: public relations, 202012 service existent by Bioscribe 2020-12-10
Resolve Biosciences–High-Tech Gründerfonds: investment, 202012 financing round Series A totalling $24m incl co-investor HTGF 2020-12-10
Resolve Biosciences–MasterMind Advisory Services: investment, 202012 financing round Series A totalling $24m incl co-lead investor MasterMind 2020-12-10
Resolve Biosciences–PERSON: investment, 202012 financing round Series A totalling $24m incl co-investor John Shoffner 2020-12-10
Resolve Biosciences–PS Capital Management: investment, 202012 financing round Series A totalling $24m incl co-lead investor PS Capital 2020-12-10
Resolve Biosciences–SEVERAL: investment, 202012 financing round Series A $24m co-led by PS Capital Management + MasterMind Advisory Services 2020-12-10
Curexsys–Evotec: investment, 202012 seed financing round totalling €8.2m incl Evotec acquiring 37% equity stake 2020-12-09
Curexsys–Sartorius: investment, 202012 seed financing round totalling €8.2m incl Sartorius acquiring 21% equity stake 2020-12-09
Curexsys–SEVERAL: investment, 202012 seed financing round €8.2m led by Evotec + Sartorius 2020-12-09
Novartis–RetinAI Medical: AI-based image analysis, 202012– collab expansion master agreement using RetinAI Discovery platform in ophthalmology 2020-12-08
RetinAI Medical–Charles Consultants: public relations, 202012 service existent by Sue Charles 2020-12-08
Biomes NGS–GPS Ventures: investment, 202012 pre-series A investment €2m from GPS Ventures GmbH 2020-12-07
Boehringer–Proxygen: molecular glue degraders, 202012– collab + license agreem developm in combi with PROTACs against oncogenic targets 2020-12-07
MaaT Pharma–Céleste Management: investment, 202012 financing round Series B extension totalling €7.35m incl new + co-investor Céleste Management 2020-12-01
MaaT Pharma–SEVERAL: investment, 202012 financing round Series B extension €7.35m led by Bpifrance bringing total Series B to €25.35m 2020-12-01
MaaT Pharma–SkyViews Life Science: investment, 202012 financing round Series B extension totalling €7.35m incl new + co-investor SkyViews Life Science 2020-12-01
Noema Pharma–SEVERAL: investment, 202012 financing round Series A CHF54m ($59m) co-led by Sofinnova Partners + Polaris Partners 2020-12-01
Slack Technologies–Salesforce: investment, 202012– acquisition $27.7b in cash + shares of Slack by Salesforce ANNOUNCED 2020-12-01
Adrenomed–HBM: investment, 202011 financing round Series E totalling €22.2m incl existing + co-lead investor HBM Healthcare Investments 2020-11-30
Adrenomed–SEVERAL: investment, 202011 financing round Series E €22.2m co-led by Wellington Partners + HBM 2020-11-30
Adrenomed–Wellington Partners: investment, 202011 financing round Series E totalling €22.2m incl existing + co-lead investor Wellington Partners 2020-11-30
BioNTech–InstaDeep: AI-based drug discovery, 2019– collab initiated in 2019 2020-11-25
BioNTech–InstaDeep: AI-based drug discovery, 202011– strategic collab incl joined AI Innovation Lab to develop immunotherapies 2020-11-25
Emergence Therapeutics–High-Tech Gründerfonds: investment, 202011 follow-on seed financing round incl lead investor HTGF 2020-11-25
Emergence Therapeutics–SEVERAL: investment, 202011 follow-on seed financing round led by HTGF 2020-11-25
Innatera Nanosystems–btov Partners: investment, 202011 seed financing round totalling €5m incl co-lead investor btov Industrial Technologies Fund 2020-11-25
Innatera Nanosystems–MIG Fonds: investment, 202011 seed financing round totalling €5m incl co-lead investor MIG Verwaltungs AG 2020-11-25
Innatera Nanosystems–SEVERAL: investment, 202011 seed financing round €5m co-lead by MIG Verwaltungs AG + btov Industrial Technologies Fund 2020-11-25
Atai Life Sciences–SEVERAL: investment, 202011 financing round Series C $125m incl $32m converted debt co-led by Apeiron + Peter Thiel + Catalio 2020-11-23
Voluntis–Debiopharm: investment, 202011 capital increase totalling €5.93m incl €3.92m from new + lead investor Debiopharm Innovation Fund 2020-11-23
Voluntis–Indigo (Eric Carreel): investment, 202011 capital increase totalling €5.93m incl €1m from existing + co-investor Indigo 2020-11-23
Voluntis–SEVERAL: investment, 202011 capital increase €5.93m net €5.7m led by Debiopharm Innovation Fund 2020-11-23
SynOx Therapeutics–Roche: emactuzumab, 202011 excl ww rights for developm + production + commercialisation 2020-11-19
SynOx Therapeutics–SEVERAL: investment, 202011 financing round Series A €37m co-led by HealthCap + Medicxi with Forbion + Gimv 2020-11-19
Pharvaris–Bain Capital: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Bain Capital Life Sciences 2020-11-18
Pharvaris–Cormorant Asset Management: investment, 202011 financing round Series C totalling $80m incl new + co-investor Cormorant Asset Management 2020-11-18
Pharvaris–Foresite Capital: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Foresite Capital 2020-11-18
Pharvaris–General Atlantic: investment, 202011 financing round Series C totalling $80m incl new + co-lead investor General Atlantic 2020-11-18
Pharvaris–Rockefeller: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Venrock Health Capital Partners 2020-11-18
Pharvaris–SEVERAL: investment, 202011 financing round Series C $80m co-led by Viking Global Investors + General Atlantic 2020-11-18
Pharvaris–VenBio: investment, 202011 financing round Series C totalling $80m incl existing + co-investor venBio Partners 2020-11-18
Pharvaris–Viking Global Investors: investment, 202011 financing round Series C totalling $80m incl new + co-lead investor Viking Global Investors 2020-11-18
Roche–Lead Pharma: small-molecule immuno modulators, 202011– collab + license agreem up to €260m incl €10m upfront plus royalties 2020-11-16
Start Codon–Novartis: investment, 202011 closing of Start Codon Fund I LP totalling £15m incl LP Novartis International AG 2020-11-16
Start Codon–SEVERAL: investment, 202011 closing of Start Codon Fund I LP at £15m incl LPs Novartis International AG + Cambridge Innovation Capital 2020-11-16
m2p-labs–Danaher: investment, 202011 acquisition of m2p-biolabs by Beckman Coulter Life Sciences 2020-11-12
Metagenomi–Agent Capital: investment, 202011 financing round Series A totalling $65m incl co-investor Agent Capital 2020-11-12
Metagenomi–Bayer: investment, 202011 financing round Series A totalling $65m incl co-lead investor Leaps by Bayer 2020-11-12
Metagenomi–HOF Capital: investment, 202011 financing round Series A totalling $65m incl co-investor HOF Capital 2020-11-12
Metagenomi–Humboldt Fund: investment, 202011 financing round Series A totalling $65m incl co-lead investor Humboldt Fund 2020-11-12
Metagenomi–InCube Ventures: investment, 202011 financing round Series A totalling $65m incl co-investor InCube Ventures 2020-11-12
Metagenomi–SEVERAL: investment, 202011 financing round Series A $65m co-led by Leaps by Bayer + Humboldt Fund 2020-11-12
Metagenomi–Sozo Ventures: investment, 202011 financing round Series A totalling $65m incl co-investor Sozo Ventures 2020-11-12
Synendos Therapeutics–SEVERAL: investment, 202011 financing round Series A CHF20m co-led by Kurma Partners + Sunstone LSV 2020-11-12
MorphoSys–Cherry Biolabs: Hemibody technology, 202011– license €na to apply Hemibody technology to six exclusive targets 2020-11-11
Catalym–Bavaria (govt): investment, 202011 financing round Series B totalling €50m incl co-investor Wachstumsfonds Bayern 2020-11-10
Catalym–Germany (govt): investment, 202011 financing round Series B totalling €50m incl co-investor Coparion 2020-11-10
Catalym–Novartis: investment, 202011 financing round Series B totalling €50m incl co-investor Novartis Venture Fund 2020-11-10
Catalym–SEVERAL: investment, 202011 financing round Series B €50m led by Vesalius Biocapital III 2020-11-10
Catalym–Vesalius Biocapital: investment, 202011 financing round Series B totalling €50m incl lead investor Vesalius Biocapital III 2020-11-10
Roche–Cevec: cell line technology, 202011– license €na to Elevecta technology for manufacutring of AAV vectors for gene therapies 2020-11-10
Apeiron–Domainex: drug discovery services, 202011– collab expansion supply of lead optimisation services for Cbl-b targeting APN431 compound series 2020-11-09
Vera Therapeutics–Merck (DE): atacicept, 202011– license for 10% equity in Vera + €605m milestones + royalties 2020-11-09
Vera Therapeutics–Merck (DE): investment, 202011 Merck reveices 10% equity in Vera Tx as part of license deal for atacicept 2020-11-09
Memo Therapeutics–Bernina BioInvest: investment, 202011 financing round Series B totalling CHF14m incl new + co-investor Bernina BioInvest 2020-11-05
Memo Therapeutics–Halsin Partners: public relations, 202011 service existent by Halsin Partners 2020-11-05
Memo Therapeutics–Jaquet Partners: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Jaquet Partners 2020-11-05
Memo Therapeutics–OTHER: investment, 202011 financing round Series B totalling CHF14m incl new private investors 2020-11-05
Memo Therapeutics–Redalpine: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Redalpine 2020-11-05
Memo Therapeutics–Schroders: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Schroder Adveq 2020-11-05
Memo Therapeutics–SEVERAL: investment, 202011 financing round Series B CHF14m led by Swisscanto by ZKB 2020-11-05
Memo Therapeutics–Verve Capital Partners: investment, 202011 financing round Series B totalling CHF14m incl existing + co-investor Investiere 2020-11-05
Memo Therapeutics–Zürcher Kantonalbank: investment, 202011 financing round Series B totalling CHF14m incl existing + lead investor Swisscanto by ZKB 2020-11-05
Corlieve Therapeutics–SEVERAL: investment, 202011 seed financing round from Kurma Partners + Idinvest Partners + Pureos Bioventures 2020-11-02
Kiadis–Sanofi: investment, 202011– cash tender offer €308m for Kiadis Pharma NV at €5.45 per share (272% premium over closing price on 30 Oct) 2020-11-02
Polaris Science (SG)–Nynomic: plant phenotyping, 202011– distribution in Singapore + Malaysia of LemnaTec solutions for phenotyping + seed testing 2020-11-01
TVM–Lilly: investment, 202010 final closing totalling $478m of fund TVM Life Science Innovation II incl investor Eli Lilly 2020-10-27
TVM–OCP Capital: investment banking, –202010 supply service OCP supports fund raising for $478m TMV LSI II fund 2020-10-27
TVM–SEVERAL: investment, 202010 final closing of $478m of fund TVM Life Science Innovation II incl Eli Lilly 2020-10-27
AskBio–Bayer: investment, 202010 acquisition by Bayer for $2b upfront plus $2b milestones 2020-10-26
Eternygen–SEVERAL: investment, 202010 financing round Series A2 1st closing €5m led by Evotec 2020-10-26
MD Biosciences–MLM Medical Labs: investment, 202010 acquisition of MD Biosciences Inc by MLM Medical Labs 2020-10-26
next pagenext page 1 2 3 ... 29 30 31  next pagenext page



Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

» top